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Background
Sensory neuropathic symptoms are some of the most fre-
quent presentations of patients on antiretroviral (ARV)
therapy. The severity of these symptoms varies remarkably
from patient to patient and if debilitating enough, may
interfere with drug adherence and quality of life. This has
been observed in some centres. Nucleoside analogue
reverse transcriptase inhibitors, which form the backbone
of first-line ARV therapy in most resource-limited settings,
have long been associated with toxic neuropathy. The sub-
ject is further compounded by the co-administration of
other chemotherapeutic agents with proven neurotoxic-
ity.
Methods
A cross-sectional descriptive study was done. Our study
population included all ARV naïve adult patients of Gede
Foundation who have been on the D4T-NVP-3TC combi-
nation therapy for a minimum of 12 months. Question-
naires were administered to patients, and their responses
analysed.
Summary of results
A total of 127 patients, 71 females [55.9%] and 56 males
[44.1%] responded to our questionnaire. Mean age of
patients was 34.3 years. Mean duration of HIV infection
was 32 months. Mean duration of ARV intake was 20
months. 60% of patients had at least one type of sensory
neuropathy. Of these, 73.5% of them had been on HAART
for at least 18 months. 75% of those with symptoms had
them after commencing HAART, while 25% of them had
symptoms before starting HAART. Mean time to onset of
symptoms was 13 months. "Pins and needles" sensations
on hands and feet, was the most frequently observed
symptom [32.8%], followed by numbness in the feet
[24.5%], burning sensations in the limbs [20.6%], cold
sensations in the feet [12.6%], and weakness in the limbs
[9.5%]. 69.5% of patients visited the doctor due to the
symptoms. Of these, 48% thought prescriptions were very
helpful, 36% noticed only slight improvement, while
16% did not notice any improvement in symptoms. None
of the patients reported stopping ARVs due to neuropathic
symptoms.
Conclusion
Sensory neuropathy is a common and frequently unrecog-
nised complication of antiretroviral therapy which clini-
cians must constantly be on the look out for. However, it
was not associated with interruption of ARV therapy in
our patients. Symptomatic treatment and use of ARVs
with less neurotoxicity can help improve the quality of life
of patients who experience it.
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